Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011.

Authors: Centers for Disease Control and Prevention (CDC),Dunne EF,Markowitz LE,Chesson H,Curtis C,Saraiya M,Gee J,Unger ER,
Address:
Journal: MMWR Morb Mortal Wkly Rep.

Publication: 2011 Dec 23;60(50):1705-8.

abstract

On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of quadrivalent human papillomavirus (HPV) vaccine (HPV4; Gardasil, Merck & Co. Inc.) in males aged 11 or 12 years. ACIP also recommended vaccination with HPV4 for males aged 13 through 21 years who have not been vaccinated previously or who have not completed the 3-dose series; males aged 22 through 26 years may be vaccinated. These Recommendations replace the October 2009 ACIP guidance that HPV4 may be given to males aged 9 through 26 years. For these recommendations, ACIP considered information on vaccine efficacy (including data available since October 2009, on prevention of grade 2 or 3 anal intraepithelial neoplasia [AIN2/3], a precursor of anal cancer), vaccine safety, estimates of disease and cancer resulting from HPV, cost-effectiveness, and programmatic considerations. The evidence for HPV4 vaccination of males was evaluated using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methods.

Related Articles
FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
MMWR Morb Mortal Wkly Rep. 2010
FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2010 May 28; 59(20):630-2.
FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
MMWR Morb Mortal Wkly Rep. 2010
FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2010 May 28; 59(20):626-9.
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2007
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007 Mar 23; 56(RR-2):1-24.
Review Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
Postgrad Med. 2010
Review Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
Broomall EM, Reynolds SM, Jacobson RM. Postgrad Med. 2010 Mar; 122(2):121-9.
Review The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
Ann Pharmacother. 2010
Review The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
Yancey AM, Pitlick JM, Forinash AB. Ann Pharmacother. 2010 Jul-Aug; 44(7-8):1314-8. Epub 2010 May 25.
Acceptability of HPV vaccines and associations with perceptions related to HPV and HPV vaccines among men who have sex with men in Hong Kong.
PLoS One. 2013
Acceptability of HPV vaccines and associations with perceptions related to HPV and HPV vaccines among men who have sex with men in Hong Kong.
Lau JT, Wang Z, Kim JH, Lau M, Lai CH, Mo PK. PLoS One. 2013; 8(2):e57204. Epub 2013 Feb 22.
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.
J Natl Cancer Inst. 2013
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.
Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, et al. J Natl Cancer Inst. 2013 Feb 6; 105(3):175-201. Epub 2013 Jan 7.
Parent-son decision-making about human papillomavirus vaccination: a qualitative analysis.
BMC Pediatr. 2012
Parent-son decision-making about human papillomavirus vaccination: a qualitative analysis.
Alexander AB, Stupiansky NW, Ott MA, Herbenick D, Reece M, Zimet GD. BMC Pediatr. 2012 Dec 14; 12:192. Epub 2012 Dec 14.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.